The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Sarepta Therapeutics Inc

Nasdaq: SRPT
Last

(U.S.) $61.41

Today's change+0.43 +0.71%
Updated September 30 4:00 PM EDT. Delayed by at least 15 minutes.
 

Sarepta Therapeutics Inc

Nasdaq: SRPT
Last

(U.S.) $61.41

Today's change+0.43 +0.71%
Updated September 30 4:00 PM EDT. Delayed by at least 15 minutes.

Sarepta Therapeutics Inc up (U.S.)$0.43

Sarepta Therapeutics Inc closed up Friday by (U.S.)$0.43 or 0.71% to (U.S.)$61.41. Over the last five days, shares have gained 6.19% and are currently 3.64% off of the 52-week high. Shares have outperformed the S&P 500 by 78.32% during the last year.

Key company metrics

  • Open(U.S.) $61.17
  • Previous close(U.S.) $60.98
  • High(U.S.) $62.23
  • Low(U.S.) $59.60
  • Bid / Ask(U.S.) $61.42 / (U.S.) $61.80
  • YTD % change+59.18%
  • Volume2,507,794
  • Average volume (10-day)12,733,380
  • Average volume (1-month)6,032,512
  • Average volume (3-month)4,771,587
  • 52-week range(U.S.) $8.00 to (U.S.) $63.73
  • Beta1.09
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$5.35
Updated September 30 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-19,049.56%

Sarepta Therapeutics Inc has a net profit margin of -19,049.56%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.19%Sector:HealthcareIndustry:Biotechnology

Latest Company News

  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2016Q1/2016Q4/2015Q3/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015
Revenue0010
Total other revenue--------
Total revenue0010
Gross profit--------
Total cost of revenue--------
Total operating expense62606652
Selling / general / administrative18212415
Research & development44394137
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-62-60-64-52
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-62-60-65-52
Income after tax-62-60-65-52
Income tax, total--------
Net income-62-60-65-52
Total adjustments to net income--------
Net income before extra. items-62-60-65-52
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-62-60-65-52
Inc. avail. to common incl. extra. items-62-60-65-52
Diluted net income-62-60-65-52
Dilution adjustment--------
Diluted weighted average shares46464542
Diluted EPS excluding extraordinary itemsvalue per share-1.35-1.31-1.44-1.25
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share-1.35-1.31-1.44-1.25